Clinical Trials Logo
  1. Home
  2. Proliferative Vitreoretinopathy
  3. NCT04830878

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients — SIGHT  

Proliferative Vitreoretinopathy Clinical Trial

Official title:
A Phase I, Multicenter, Uncontrolled, Open Label Study Assessing the Efficacy and Safety of a Combination of Systemic and Intravitreal Injections of Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients With RheGmatogenous Retinal DetacHmenT (the SIGHT Study)

Clinical Trial Summary

Rhegmatogenous retinal detachment (RRD) is a sight-threatening condition. Children with RRD usually present late with clinical features of longstanding RRD, specifically a serious condition named: proliferative vitreoretinopathy (PVR). Therefore, children with RRD often have poorer outcomes. The objective of this study is to investigate the efficacy and safety of methotrexate in the treatment and prevention of PVR. Methotrexate is a medication that has been used to treat inflammatory conditions in children and adults for a long time and it has been recently used to treat PVR in adults.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04830878
Study type Interventional
Source Stanford University
Contact
Status Withdrawn
Phase Phase 1
Start date April 2021
Completion date April 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT01445028 - Isotretinoin for Proliferative Vitreoretinopathy Phase 4
Recruiting NCT00370760 - Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Phase 3
Completed NCT00000140 - The Silicone Study Phase 3
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Recruiting NCT04580147 - Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair Phase 2
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Completed NCT04136366 - The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Phase 3
Recruiting NCT06289205 - "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Phase 1/Phase 2
Completed NCT00373282 - Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Phase 3
Completed NCT01995045 - Postoperative Pain Control Following Vitreoretinal Surgery Phase 4
Completed NCT04490876 - Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Completed NCT02192970 - Bevacizumab Against Recurrent Retinal Detachment Phase 2
Not yet recruiting NCT04682054 - Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics N/A
Recruiting NCT05660447 - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Phase 2/Phase 3
Not yet recruiting NCT06033703 - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Phase 1/Phase 2
Active, not recruiting NCT00371020 - The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Phase 3